News

Menarini catches ADC fever
Enlarge image

BusinessItalyUK

Menarini catches ADC fever

30.10.2012 - Italian Menarini Group and Oxford Biotherapeutics want to jointly develop five antibody-based drugs. The deal is worth €800m.

„I am very pleased to announce this novel strategic alliance, which foresees the development and manufacture of up to five cancer treatment programmes and a total investment of €800m“, said Alberto Giovanni Aleotti, a member of the Board of Florence-based Menarini Group, on 29 October 2012. The ally comes from the UK. The biotech company Oxford Biotherapeutics (OBT) will contribute five of its about 25 antibody and antibody drug conjugate (ADC) programmes, each of which addresses a different cancer indication via a different novel oncology target. Menarini, however, brings in its clinical knowledge so that under the agreements of the collaboration, the Italian pharma corporation will lead the efforts in the manufacture and clinical development of each programme, while OBT will provide the proprietary cancer target, antibody and arming technologies.

The companies plan to work together for about 10 years. Once clinical proof of concept of one or the other programme has been achieved, OBT will complete the clinical development and commercialise these novel antibody-based products in North America and Japan, whilst Menarini will develop and commercialise the products in Europe, CIS, Asia and Latin America. Menarini’s fortitude comes a bit as a surprise because the pharma business has already burned its fingers in antibody-based drugs: Just 16 months ago a Phase III trial of abagovomab, a mouse anti-idiotype monoclonal antibody mimicking the CA-125 antigen found on ovarian cancer cells, could not fulfil the expectations raised in previous studies.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/menarini-catches-adc-fever.html

ResearchUK

30.01.2015 AstraZeneca has joined forces with four research collaborations to use breakthrough CRISPR gene editing technology across its drug discovery platform.

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%
  • ADDEX3.28 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%

TOP

  • CYTOS0.36 CHF56.5%
  • FORMYCON15.48 EUR53.6%
  • ADDEX3.28 CHF41.4%

FLOP

  • BIOFRONTERA1.93 EUR-16.1%
  • ACTELION100.80 CHF-13.3%
  • MOLOGEN5.75 EUR-9.4%

TOP

  • SANTHERA105.00 CHF2544.8%
  • WILEX1.96 EUR168.5%
  • FORMYCON15.48 EUR103.7%

FLOP

  • CYTOS0.36 CHF-90.1%
  • 4SC0.84 EUR-49.7%
  • MOLOGEN5.75 EUR-49.7%

No liability assumed, Date: 30.01.2015